Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Haoyuan Chemexpress CoSHSE:688131 +3.19%86 Return-on-Tangible-Equity is 10.27% as of Mar. 2026, which is 33% below its 10-year median of 15.43. GuruFocus rates SHSE:688131 with a GF Score™ of 86/100 and a GF Value™ of ¥66.97 (Significantly Overvalued). The stock has 11 warning signs investors should review. Among 894 Drug Manufacturers companies, Shanghai Haoyuan Chemexpress Co ranks better than 54.36% on this metric.
The historical rank and industry rank for Shanghai Haoyuan Chemexpress Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688131'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.36 Med: 15.43 Max: 41.57
Current: 9.34
During the past 13 years, Shanghai Haoyuan Chemexpress Co's highest Return-on-Tangible-Equity was 41.57%. The lowest was 6.36%. And the median was 15.43%.
SHSE:688131's Return-on-Tangible-Equity is ranked better than 54.36% of 894
companies
in the Drug Manufacturers industry
Industry Median: 7.895
vs SHSE:688131: 9.34
Shanghai Haoyuan Chemexpress Co (SHSE:688131) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shanghai Haoyuan Chemexpress Co Return-on-Tangible-Equity Related Terms
Shanghai Haoyuan Chemexpress Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haoyuan Chemexpress Co Return-on-Tangible-Equity Chart
SHSE:688131 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Haoyuan Chemexpress Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haoyuan Chemexpress Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Haoyuan Chemexpress Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Shanghai Haoyuan Chemexpress Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.27% mean?
Shanghai Haoyuan Chemexpress Co (SHSE:688131) has a Return-on-Tangible-Equity of 10.27% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai Haoyuan Chemexpress Co and its competitors. This is 33% below median its historical median of 15.43. Over the past decade, Shanghai Haoyuan Chemexpress Co's Return-on-Tangible-Equity has ranged from 6.36 to 41.57. According to the industry distribution chart, Shanghai Haoyuan Chemexpress Co ranks #408 out of 894 companies in the Drug Manufacturers industry, placing it in the top 45.6%.
Is Shanghai Haoyuan Chemexpress Co's Return-on-Tangible-Equity too high?
Shanghai Haoyuan Chemexpress Co's current Return-on-Tangible-Equity of 10.27% is 33% below median its 10-year median of 15.43. Over the past 10 years, this metric has ranged from a low of 6.36 to a high of 41.57. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Shanghai Haoyuan Chemexpress Co's value of 10.27% is 30.1% above this industry median. Based on the distribution chart, Shanghai Haoyuan Chemexpress Co ranks #408 out of 894 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Haoyuan Chemexpress Co has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haoyuan Chemexpress Co's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Haoyuan Chemexpress Co ranks #408 out of 894 companies for Return-on-Tangible-Equity. This puts Shanghai Haoyuan Chemexpress Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Shanghai Haoyuan Chemexpress Co's value of 10.27% is 30.1% above this benchmark. Historically, Shanghai Haoyuan Chemexpress Co's own Return-on-Tangible-Equity has ranged from 6.36 to 41.57 over the past decade. While the company's 10-year median is 15.43 vs. the industry median of 7.90, Shanghai Haoyuan Chemexpress Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 894 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haoyuan Chemexpress Co's current Return-on-Tangible-Equity of 10.27% is 30.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai Haoyuan Chemexpress Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haoyuan Chemexpress Co's current Return-on-Tangible-Equity is 10.27%, which is 33% below median its own 10-year median of 15.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haoyuan Chemexpress Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co (SHSE:688131) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥66.97, compared to a current price of ¥100.09 — trading 49.5% above its estimated fair value. The current Return-on-Tangible-Equity is 10.27%, which is 33% below median its 10-year median of 15.43 and 30.1% above the Drug Manufacturers industry median of 7.90. Shanghai Haoyuan Chemexpress Co's overall GF Score™ is 86/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shanghai Haoyuan Chemexpress Co (SHSE:688131), the current Return-on-Tangible-Equity is 10.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haoyuan Chemexpress Co (SHSE:688131) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co stock appears to be overvalued.
The current stock price of ¥100.09 is trading 49.5% above its estimated GF Value™ of ¥66.97.
GuruFocus considers Shanghai Haoyuan Chemexpress Co to be Significantly Overvalued.
Key valuation signals for SHSE:688131:
Return-on-Tangible-Equity: 10.27% (33% below median its 10-year median of 15.43)
GF Value™: ¥66.97 vs. price of ¥100.09 (49.5% above fair value)
Industry Position: 30.1% above the Drug Manufacturers median (#408 of 894)
No single metric tells the full story. See the SHSE:688131 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haoyuan Chemexpress Co Ltd focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. The company's comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. It is a one-stop service platform to support client's projects from early drug discovery, process development to commercialization. The company is committed to delivering high-quality products and CMC services to clients across the entire life cycle of drug development.
86GF Score
Get the complete analysis for SHSE:688131
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688131 has been successfully added to your 
